BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  TTP Group Announces the Sale of LEX Diagnostics

  April 20, 2026

   · 

  2 min read
• Press Releases

  Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

  April 20, 2026

   · 

  6 min read
• Press Releases

  Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy

  April 20, 2026

   · 

  4 min read
• Press Releases

  Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter

  April 20, 2026

   · 

  4 min read
• Press Releases

  Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis

  April 20, 2026

   · 

  4 min read
• Press Releases

  Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

  April 20, 2026

   · 

  8 min read
• Press Releases

  BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

  April 20, 2026

   · 

  3 min read
• Press Releases

  Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

  April 20, 2026

   · 

  11 min read
• Press Releases

  LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

  April 20, 2026

   · 

  6 min read
• Press Releases

  Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

  April 20, 2026

   · 

  5 min read